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Abstract
Introduction: As cancer cells are affected by many factors in their microenvironment, a major challenge is to isolate the
effect of a specific factor on cancer stem cells (CSCs) while keeping other factors unchanged. We have developed a synthetic
inert 3D polyethylene glycol diacrylate (PEGDA) gel culture system as a unique tool to study the effect of
microenvironmental factors on CSCs response. We have reported that CSCs formed in the inert PEGDA gel by
encapsulation of breast cancer cells maintain their stemness within a certain range of gel stiffness. The objective was to
investigate the effect of CD44 binding peptide (CD44BP) conjugated to the gel on the maintenance of breast CSCs.
Methods: 4T1 or MCF7 breast cancer cells were encapsulated in PEGDA gel with CD44BP conjugation. Control groups
included dissolved CD44BP and the gel with mutant CD44BP conjugation. Tumorsphere size and density, and expression of
CSC markers were determined after 9 days. For in vivo, cell encapsulated gels were inoculated in syngeneic Balb/C mice and
tumor formation was determined after 4 weeks. Effect of CD44BP conjugation on breast CSC maintenance was compared
with integrin binding RGD peptide (IBP) and fibronectin-derived heparin binding peptide (FHBP).
Results: Conjugation of CD44BP to the gel inhibited breast tumorsphere formation in vitro and in vivo. The ability of the
encapsulated cells to form tumorspheres in the peptide-conjugated gels correlated with the expression of CSC markers.
Tumorsphere formation in vitro was enhanced by FHBP while it was abolished by IBP.
Conclusion: CD44BP and IBP conjugated to the gel abolished tumorsphere formation by encapsulated 4T1 cells while FHBP
enhanced tumorsphere formation compared to cells in the gel without peptide. The PEGDA hydrogel culture system
provides a novel tool to investigate the individual effect of factors in the microenvironment on CSC maintenance without
interference of other factors.
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Introduction
Breast cancer is the most common type of cancer, which
accounts for 23% of all cancers in women worldwide [1]. Breast
tumors are highly heterogeneous, in which cells with self-renewal
and highly invasive capacity coexist with cells that are more
differentiated and non-invasive [2]. Increasing evidence suggests
that the heterogeneity of the tumor tissue is rooted in the existence
of cancer stem cells (CSCs) [3]. Consistent with this notion, the
triple negative breast cancer, which is one of the most aggressive
types of breast cancer, contains a high fraction of CSCs [4,5].
Therefore, understanding the mechanism of CSC maintenance is
critical for breast cancer prevention and treatment.
The maintenance of CSCs, like that of normal stem cells, is
regulated by the microenvironment. Interactions between the stem
cells and support cells, interactions between stem cells and
extracellular matrix (ECM), the composition of ECM and the
physicochemical properties of the environment are key contribut-
ing factors in stem cell maintenance [6]. Two major factors hinder
the study of microenvironment on tumor development in vivo.
First, the process of cancer development takes many years, which
makes it difficult to follow. Second, it is difficult to study the effect
of a specific factor in the microenvironment while keeping all other
factors unchanged, as cancer cells are affected by many factors
simultaneously. Many in vitro studies have provided insight on the
regulation of CSC fate by the microenvironment. However, most
in vitro studies use 2-dimensional (2D) tissue culture plates coated
with ECM components to investigate cell signaling and behavior,
which may not reflect those conditions under 3-dimensional (3D)
physiological environment. Therefore, the 3D in vitro cell culture
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system has emerged as another approach to investigate the
interaction between the microenvironment and cancer cells. Most
commonly used matrices for 3D cell culture are type I collagen
and Matrigel [7,8]. However, these matrices contain many cell
regulatory factors, which make it difficult to determine the role of
individual environmental factors on cell behavior. We have
developed an inert polyethylene glycol diacrylate (PEGDA) based
in vitro 3D cell culture system which does not have cell interaction
ligands, thus providing a unique tool to study tumor microenvi-
ronment in vitro. More importantly, the CSCs of breast cancer can
maintain their stemness and proliferate while the growth of non-
CSCs is inhibited when encapsulated in the PEGDA gel within
a certain range of elastic moduli.
In this study, the inert PEGDA hydrogel, in a certain range of
moduli, was used as a 3D cell culture model to investigate the role
of cell binding peptides in the maintenance of breast CSCs. More
specifically, we investigated the effect of CD44 binding peptide
conjugated to the gel or dissolved in the gel on the maintenance of
CSCs, because CD44 expression is the most widely used marker
for characterization and identification of breast CSCs [9,10].
CD44 is a cell membrane glycoprotein involved in cell migration
and adhesion [11]. CD44 has been used for CSC detection and
targeting but the mechanism of its involvement in the maintenance
of CSCs is not clear. Antibodies against CD44 inhibit breast tumor
growth and prevent cancer recurrence [12]. Anti-CD44 antibodies
are found to induce the differentiation of acute myeloid leukemia
(AML) stem cells [13]. A CD44 exon v6-specific antibody blocks
the metastasis of rat pancreatic cancer cells [14]. Therefore,
investigating the role of CD44 binding peptide on regulation of
CSCs can provide critical information on the behavior of breast
CSCs.
For the purpose of comparison and proof of principle, we also
conjugated an integrin binding RGD peptide (IBP) and a fibro-
nectin-derived heparin-binding peptide (FHBP) to the gel to
investigate their effects on breast CSC maintenance in vitro. We
chose those two peptides because fibronectin is one of the major
components of ECM that mediates cell adhesion, and integrins are
the major receptors on the cell surface that sense the environ-
mental cues. Our results show that conjugation of FHBP to the gel
matrix enhanced tumorsphere formation by the encapsulated 4T1
breast cancer cells while CD44BP and IBP abolished sphere
formation in vitro. Furthermore, results demonstrate that the inert
PEGDA hydrogel can be used as a model 3D matrix to study the
role of individual factors in the tumor microenvironment on
tumorigenesis and maintenance of CSCs.
Materials and Methods
Materials
Polyethylene glycol (PEG, nominal molecular weights 4.6 kDa),
dichloromethane (DCM), N,N-dimethylformamide (DMF), diiso-
propylcarbodiimide (DIC), 4-dimethylaminopyridine (DMAP),
trifluoroacetic acid (TFA), triisopropylsilane (TIPS), diethyl ether,
and hexane were purchased from Acros (Fairfield, OH). The Rink
Amide NovaGelTM resin, all Fmoc-protected amino acids, and
hydroxybenzotriazole (HOBt) were purchased from Novabiochem
(EMD Biosciences, San Diego, CA). Calcium hydride, triethyla-
mine (TEA), paraformaldehyde, 4,6-diamidino-2-phenylindole
(DAPI), insulin, penicillin, and streptomycin were purchased from
Sigma-Aldrich (St. Louis, MO). Acetomethoxy derivative of
calcein (cAM) and ethidium homodimer (EthD) were purchased
from Molecular Probes (Life Technologies, Grand Island, NY).
Basic fibroblast growth factor (bFGF) and epidermal growth factor
(EGF) were purchased from Lonza (Allendale, NJ). Bovine serum
albumin (BSA) was obtained from Jackson ImmunoResearch
(West Grove, PA). Dulbecco’s phosphate-buffer saline (PBS),
trypsin-EDTA, RPMI-160 cell culture medium, fetal bovine
serum (FBS), Alexa FluorH 594 Phalloidin, and Quant-it Pico-
Green dsDNA reagent kit were purchased from Invitrogen
(Carlsbad, CA). Horse serum and DMEM-F12 medium were
purchased from PAA Laboratories (Etobicoke, Ontario) and
MediaTech (Manassas, VA), respectively. Spectro/Por dialysis
tube (molecular weight cutoff 3.5 kDa) was purchased from
Spectrum Laboratories (Rancho Dominquez, CA). DCM was
purified by distillation over calcium hydride. All other solvents
were reagent grade and were used as received without further
purification. The anti-Actin, anti-VEGFa and anti-Vimentin
antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Fluorescent conjugated secondary antibodies were
obtained from Invitrogen. 4T1 mouse breast carcinoma cell line
was developed by Dr. Suzanne Ostrand-Rosenberg group and
available from ATCC (Manassas, VA) [15]. The cell line was
characterized and purified by Dr. Ralph A. Reisfeld at the Scripps
Research Institute (La Jolla, CA) [16]. 4T1 cells were a donation
from Dr. Reisfeld under a Material Transfer Agreement. MCF7
human breast adenocarcinoma cell line and MCF10a non-
tumorigenic epithelial cell line were obtained from ATCC.
Macromer Synthesis and Characterization
The PEG macromer was functionalized with acrylate groups to
produce PEGDA by the reaction of acryloyl chloride with
hydroxyl end-groups of PEG. TEA was used as the reaction
catalyst. Prior to the reaction, PEG was dried by azeotropic
distillation from toluene to remove residual moisture. The polymer
was dissolved in dried DCM in a reaction flask and the flask was
immersed in an ice bath to cool the solution. In a typical reaction,
5.6 ml acryloyl chloride and 9.7 ml TEA, each dissolved in DCM,
were added drop-wise to the reaction with stirring. The reaction
was allowed to proceed for 12 h under nitrogen flow. After
completion of the reaction, the solvent was removed by rotary
evaporation and the residue was dissolved in anhydrous ethyl
acetate to precipitate the by-product triethylamine hydrochloride
salt. Next, ethyl acetate was removed by vacuum distillation; the
macromer was re-dissolved in DCM and precipitated twice in cold
ethyl ether. Then, the macromer was dissolved in dimethylsulf-
oxide (DMSO) and dialyzed against distilled deionized (DI) water
to remove the by-products. The PEGDA product was freeze-dried
and stored at 220uC. A hydrolytically degradable version of the
PEGDA gel (dPEGDA) was synthesized with a similar procedure
as described previously [17]. The chemical structure of the
functionalized macromer was characterized by a Varian Mercury-
300 1H-NMR (Varian, Palo Alto, CA) at ambient conditions with
a resolution of 0.17 Hz. The sample was dissolved in deuterated
chloroform at a concentration of 5 mg/ml and 1% v/v TMS was
used as the internal standard.
Peptide Synthesis and Characterization
CD44 binding peptide (CD44BP), integrin-binding RGD
peptide (IBP), and fibronectin-derived heparin-binding peptide
(FHBP) as well as their mutants, selected according to previous
reports [18–20], were synthesized manually on Rink Amide resin
in the solid phase using a previously described procedure [21].
The sequences of these peptides and their mutants are listed in
Table 1.
Briefly, the Fmoc-protected amino acid (6 eq.), DIC (6.6 eq.),
and HOBt (12 eq.) were added to 100 mg resin and swelled in
DMF (3 mL). Next, 0.2 mL of 0.05 M DMAP was added to the
mixture and the coupling reaction was allowed to proceed for 4–
Conjugated CD44 Peptide on Tumorsphere Formation
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6 h at 30uC with orbital shaking. The resin was tested for the
presence of unreacted amines using the Kaiser reagent [21]. If the
test was positive, the coupling reaction was repeated. Otherwise,
the resin was treated with 20% piperidine in DMF (2615 min)
and the next Fmoc-protected amino acid was coupled using the
same procedure. After coupling the last amino acid, the peptides
were functionalized with an acrylamide group directly on the
peptidyl resin by coupling acrylic acid to the N-terminal amine
group under conditions used for the amino acid coupling reaction
[21]. The acrylamide-terminated peptide was cleaved from the
resin by treating with 95% TFA/2.5% TIPS/2.5% water and
precipitated in cold ether. The acrylamide-terminated (Ac)
peptides were further purified by preparative HPLC on
a 250610 mm, 10 mm Xterra Prep RP18 column (Waters,
Milford, MA) with a flow rate of 2 mL/min using a gradient 5–
95% MeCN in 0.1% aqueous TFA at detection wavelength of
214 nm. The HPLC fraction was lyophilized and the product was
characterized with a Finnigan 4500 Electro Spray Ionization (ESI)
spectrometer (Thermo Electron, Waltham, MA).
Hydrogel Synthesis and Measurement of Modulus
The PEGDA macromer was crosslinked in aqueous solution to
form a gel by ultraviolet (UV) initiated radical polymerization with
4-(2-hydroxyethoxy)phenyl-(2-hydroxy-2-propyl) ketone (Irgacure
2959; CIBA, Tarrytown, NY) photoinitiator. Five mg of initiator
was dissolved in 1 mL PBS at 50uC. The macromer was dissolved
in PBS by vortexing and heating to 50uC. To prepare 10%
PEGDA hydrogel precursor solution, 30 mg PEGDA macromer
was mixed with 270 mL of the initiator solution. The hydrogel
precursor solution was degassed and transferred to a Teflon mold
(5 cm63 cm6500 mm), covered with a transparent glass plate and
fastened with clips. Then, the assembly was irradiated with
a BLAK-RAY 100-W mercury long wavelength (365 nm) UV
lamp (Model B100-AP; UVP, Upland, CA) for 10 min. Next, disc
shape samples were cut from the gel using an 8 mm cork borer
and swollen in PBS for 24 h at 37uC. To measure the elastic
modulus of the gel, samples were loaded on the Peltier plate of
a rheometer (TA Instruments, New Castle, DE) and subjected to
uniaxial compressive force at a displacement rate of 7.5 mm/s.
The slope of the linear fit to the stress-strain curve for 5–10%
strain was taken as the elastic modulus (E) of the gel.
Cancer Stem Cell Culture and Cell Encapsulation in the
Hydrogel
The tumor cells were cultured in RMPI-1640 medium with
10% FBS under 5% CO2 at 37uC. Cells were trypsinized after
reaching 70% confluency. The synthesized acrylamide-terminated
peptides were added to the PEGDA macromer solution and the
mixture was sterilized by filtration (220 nm filter). Next, 1.46105/
ml cells (4T1, MCF7, or MCF10a) were added to the macromer
solution and mixed gently with a pre-sterilized glass rod. The cell-
suspended hydrogel precursor solution was crosslinked with UV
for 10 min as described above. After cross-linking, the gel was cut
into disks and incubated in stem cell culture medium on ultra-low
attachment tissue culture plates under 5% CO2. The stem cell
medium consisted of DMEM-F12 supplemented with 0.4% BSA,
5 mg/ml insulin, 40 ng/ml bFGF, 20 ng/ml EGF, 5% horse
serum, 100 U/ml penicillin, and 100 mg/ml streptomycin [22].
For growing tumorspheres in suspension, trypsinized cells (4T1 or
MCF7) were cultured on ultra-low attachment tissue culture plates
with stem cell culture medium under 5% CO2 at 37uC as
described previously [22–24]. The gold standard for character-
ization of CSC tumorspheres for stemness is by the ability to form
tumor in vivo [25,26].
Cell Imaging and Determination of Cell Number
To determine cell viability, gels were stained with cAM and
EthD dyes after cell encapsulation to image live and dead cells,
respectively. Stained samples were imaged with an inverted
fluorescent microscope (Nikon Eclipse Ti-e, Nikon, Melville,
NY). Cell viability was quantified by dividing the image into
smaller squares and counting the number of live and dead cells
manually. At each time point, three gel samples were removed
from the culture medium and stained for imaging. For imaging the
encapsulated cells, gels were rinsed twice with PBS and fixed with
4% paraformaldehyde for 3 h. After fixation, cells were permea-
bilized using PBS containing 0.1% Triton X-100 for 5 min. After
rinsing, cells were incubated with Alexa 488 phalloidin (1:200
dilution) and DAPI (1:5000 dilution) to stain actin filaments of the
cell cytoskeleton and cell nuclei, respectively. Stained samples were
imaged with a Nikon Eclipse Ti-e inverted fluorescent microscope.
For determination of cell number, the gel samples were
homogenized, cells were lysed, and aliquots were used to measure
the double stranded DNA (dsDNA) content using a Quant-it
PicoGreen assay as described [27]. Briefly, an aliquot (100 mL) of
the working solution was added to 100 mL of the cell lysate and
incubated for 4 min at ambient conditions. The fluorescence of
the solution was measured with a plate reader (Synergy HT, Bio-
Tek, Winooski, VT) at emission and excitation wavelength of 485
and 528 nm, respectively. Measured fluorescent intensities were
correlated to cell numbers using a calibration curve constructed
with cells of known concentration ranging from zero to 105 cells/
mL.
Real Time PCR Analysis
Total cellular RNA of the gel samples was isolated using TRIzol
(Invitrogen) as described [27]. 250 ng of the extracted purified
RNA was reverse transcribed to cDNA by SuperScript II Reverse
Transcriptase (Invitrogen) with the random primers. The obtained
cDNA was subjected to real time quantitative polymerase chain
reaction (RT-qPCR) amplification with the appropriate gene
specific primers. RT-qPCR was performed to analyze the
differential expression of CSC markers CD44, CD24, ABCG2,
and SCA1 genes with SYBR green RealMasterMix (Eppendorf,
Hamburg, Germany) using Bio-Rad iCycler PCR system (Bio-
Rad, Hercules, CA). The expression level of GAPDH gene was
used as an internal control. The primers for real time PCR were
designed by Primer 3 software (http://frodo.wi.mit.edu). The
forward and reverse primer sequences, listed in Table 2, were
synthesized by Integrated DNA technologies (Coralville, IA). The
relative gene expression levels were quantified by the 2‘(–DDCT)
method as described [28,29]. Briefly, DCT was calculated as
DCT=CT
target gene2CT
GAPDH. DDCT of the target gene was
calculated as DDCT=DCT
experimental group2DCT
reference group. The
reference was the first time point (right after cells were
encapsulated in the gel). The relative gene expression (fold-change
Table 1. Peptides and their scrambled sequence.
Peptide name Sequence Scrambled (mutant)
CD44BP RLVSYNGIIFFLK VLFGFLKIYSRIN
IBP GRGDS GRDGS
FHBP WQPPRARI RPQIPWAR
doi:10.1371/journal.pone.0059147.t001
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compared to the reference time point) was calculated as 2‘(–
DDCT).
Flow Cytometry Analysis
Cells encapsulated in the gel were fixed with 4% para-
formaldehyde for 30 min followed by washing with PBS. Next,
the gel was incubated in oxidative degradation solution (0.1 M
CoCl in 20% hydrogen peroxide) [30]. After the gel was degraded,
cells were washed three times with cold PBS containing 5% BSA.
MCF7 cells were incubated with phycoerythrin (PE) mouse anti-
human CD24 and fluorescein isothiocyanate (FITC) mouse anti-
human CD44 (BD Biosciences, Franklin Lakes, NJ), and 4T1 cells
were incubated with PE-anti-mouse CD24 and FITC-anti-mouse
CD44 (eBioscience, San Diego, CA) in 100 ml PBS with 5% BSA
for 45 min on ice in dark. Cells were then washed with cold PBS
with 5% BSA three times and analyzed by a flow cytometer
(FC500, Beckman Coulter, Brea, CA). Flow cytometry was done
multiple times on each sample to ascertain reproducibility of the
results.
Western Blot
The cell encapsulated gel was washed with PBS and homog-
enized in RIPA buffer (1% NP40, 1% SDS, 150 mM NaCl,
20 mM Tris-Cl pH7.4, 1 mM EDTA protease inhibitors) to
extract the proteins. The homogenized sample was centrifuged for
5 min to isolate total proteins. Next, proteins were separated by
standard SDS-PAGE using Mini-gel system (Bio-Rad) and trans-
ferred to a nitrocellulose membrane by the semi-dry transfer
apparatus (Bio-Rad). Membranes were incubated in the blocking
buffer (5% fat-free dry milk in TBST buffer) at ambient conditions
for 1 h followed by incubation with primary antibodies (1:200–
1:2000) overnight at 4uC. After washing, the membrane was
incubated with HRP-conjugated secondary antibodies for 1 h at
ambient conditions. After extensive washing with TBST, the
membrane was incubated with ECL detection reagents and
exposed to an X-ray film. The intensity of the band was quantified
with the Image-J software (National Institutes of Health, Bethesda,
MD).
Tumor Growth in vivo and Measurement
To test tumor formation ability of 4T1 cells in the hydrogel, the
cell encapsulated gels were cultured in vitro in the stem cell medium
for 9 days as described above. After tumorsphere formation, gel
pieces containing 16105 tumorsphere cells were implanted
subcutaneously in syngeneic Balb/C mice (6 mice/group). Groups
included 4T1 tumorsphere cells, grown on ultra-low attachment
plates, and injected subcutaneously (control group), degradable
version of the PEGDA gel (dPEGDA) without tumor cells (control
group), 4T1 cells encapsulated in the dPEGDA and cultured
in vitro for 9 days prior to implantation, and 4T1 cells encapsulated
in CD44BP-conjugated dPEGDA gel and cultured in vitro for 9
days prior to implantation. When tumors became measurable,
tumor size and growth rate were measured and calculated as
described [31,32]. Mice were euthanized when tumor volume
reached above 1000 mm3 or 4 weeks after inoculation.
Ethics Statement
The animal study was carried out according to the guidelines for
the care and use of laboratory animals of the NIH and approved
protocol by Dorn Research Institute IACUC. Inoculation was
performed under isoflurane anesthesia. Animals were monitored
daily and all efforts were made to minimize the stress. Since 4T1,
MCF7 and MCF10a cell lines were not de novo cell lines, ethical
committee approval was not required.
Statistical Analysis
Data were expressed as means6standard deviation. Significant
differences between groups were evaluated using a two-way
ANOVA with replication test followed by a two-tailed Student’s t-
test. To account for multiple pair comparisons, p-values from the
t-test were corrected using False Discovery Rate (FDR) method
[33]. A value of p,0.05 was considered statistically significant.
Results
Sphere Formation in PEGDA Hydrogel
We have shown shat tumorsphere formation in the PEGDA gel
depended strongly on the gel modulus [34]. Both 4T1 mouse and
MCF7 human breast carcinoma cells formed spheres in the gel
with 5 kPa modulus, and the sphere formation was correlated with
Table 2. Forward and reverse sequence of the PCR primers.
PCR Primer Forward Reverse
mouse GAPDH 59-CATGGCCTTCCGTGTTCC TA-39 59-CCTGCTTCACCACCTTCTTGA-39
mouse CD44 59-GAA TGTAACCT CCGCTACG-39 59-GGAGGTGTTGGACGTGAC-39;
mouse CD24 59-CTTCTGGCACTGCTCCTACC-39 59-GAGAGAGAGCCAGGAGACCA-39
mouse ABCG2 59-AGCAGCAAGGAAAGATCCAA-39 59-GGAATACCGAGGCTGATGAA-39
mouse SCA1 59-TGGACACTTCTCACACTA-39 59-CAGAGCAAGAGGGTCTGCAGGAG-39
mouse E-Cadherin 59-ACTGTGAAGGGACGGTCAAC-39 59-GGAGCAGCAGGATCAGAATC-39
mouse N-Cadherin 59-GGGACAGGAACACTGCAAAT-39 59-CGGTTGATGGTCCAGTTTCT-39
mouse integrin aV 59-GCTTAAAGGCAGATGGCAAC-39 59-AAATGGTGATGGGAGTGAGC-39
mouse integrin b3 59-TGACATCGAGCAGGTGAAAG-39 59-GAGTAGCAAGGCCAATGAGC-39
mouse EGFR 59-CAGTGGGCAACCCTGAGTAT-39 59-GGGCCCTTAAATATGCCATT -39
human GAPDH 59-GAGTCAACGGATTTG GTCGT-39 59-TTGATTTTGGAGGGATCTCG-39
human CD44 59-GGCTTTCAATAGCACCTTGC-39 59-ACACCCCTGTGTTGTTTGCT-39
human ABCG2 59-CACCTTATTGGCCTCAGGAA-39 59-CCTGCTTGGAAGGCTCTATG-39
doi:10.1371/journal.pone.0059147.t002
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the expression of CSC markers [34]. To determine whether non-
cancerous cells could form spheres in the PEGDA gel, MCF10a
normal human breast epithelial cells were encapsulated in the gel
with 5 kPa modulus and sphere formation was compared with
those of 4T1 and MCF7 breast cancer cells. Fluorescent images a–
c in Figure 1 show that 4T1 and MCF7 cancer cells encapsulated
in the gel formed spheres but not the normal MCF10a cells,
suggesting that the spheres originated from the CSC sub-
population of 4T1 and MCF7 cancer cells. The cell number
density, sphere size, and size distribution for 4T1, MCF7 and
MCF10a cells encapsulated in the gel after 6 and 9 days
incubation in stem cell culture medium are shown in Figures 1d–
1f. The cell density of 4T1 and MCF7 cells significantly increased
for both time points, while that of MCF10a remained at a low level
(Figure 1d), suggesting that the PEGDA gel promoted the
proliferation of tumor cells, but not the normal cells. The density
of 4T1 tumorspheres was slightly higher than that of MCF7 after 6
or 9 days of incubation. 4T1 cells also formed larger spheres than
MCF7 as shown in Figure 1e. After 9 days of culturing in the gel,
nearly 40% of the 4T1 spheres were larger than 80 mm while most
of the MCF7 spheres were between 40 and 80 mm (Figure 1f).
MCF10a remained as single cells in the gel with size smaller than
20 mm. The expressions of breast CSC markers CD44, CD24, and
ABCG2 for the encapsulated cells are shown in Figures 1g–1i.
After 6 days of incubation, CD44 expression level in 4T1 and
MCF7 cells increased by 10 folds of the initial level (Figure 1g).
CD44 expression was further increased in 4T1 cells 9 days after
encapsulation. However, as reported previously, the expression of
CD44 in 4T1 and MCF7 cells started to decrease after 11 days of
incubation irrespective of the extent of cell viability and the
increase in tumorsphere size [34]. The expression of CD24 was
significantly reduced in 4T1 cells but increased slightly in MCF7
(Figure 1h). Although CD44+/CD242 cells are considered breast
CSCs, the expression of CD24 as a CSC marker in MCF7 is not
conclusive. Previous studies have indicated that CD44+/CD242
and CD44+/CD24+ cells both display CSC phenotypes in MCF7
cells [35]. The discrepancy may be due to different primers used
for real time PCR quantification, and antibodies used for cell
sorting as well as the methods used for analysis. The expression of
ABCG2, a subunit of ABC transporter that is responsible for the
drug resistance of CSCs was also increased in 4T1 and MCF7 cells
(Figure 1i). On the other hand, the expression of these markers in
MCF10a cells did not change. Figure 2 a to c shows representative
images of live (green) and dead (red) 4T1 cells encapsulated in
PEGDA gels with 5 kPa modulus after 2 (a), 6 (b) and 12 (c) days,
respectively. The insets are the corresponding figures in the 70 kPa
gel. For 5 kPa gel, cell viability after 2, 6, and 12 days increased
from 9163% to 9464% and 9762%, respectively. For the high
modulus 70 kPa gel, no tumorsphere formed and cell viability
decreased from 8964% at day 2 to 8463% and 7862% at days 6
and 12, respectively. Based on these results, the effect of peptide
conjugation on tumorsphere formation was investigated with 4T1
cells in the PEGDA gel with 5 kPa modulus and incubation time
of 9 days.
The CD44+/CD242 marker expression is widely used for
identification of breast CSCs. Flow cytometry analysis of MCF7
cells isolated from the gel is shown in Figure 3. The percentage of
CD44+/CD242 cells before encapsulation in the gel was 2%
(Figure 3a) but it increased to 53% (Figure 3b) and 76% (Figure 3c)
after 3 and 8 days incubation in the gel, respectively. However, the
percent CD44+/CD242 cells decreased to 27% after 11 days
incubation in the gel (Figure 3d). These results are consistent with
our previous results in which the CD44 mRNA expression of 4T1
and MCF7 cells initially increased with time, then began to
decrease after 14 days of incubation in the gel [34]. The flow
cytometry results demonstrate that the percentage of CSCs in the
population of cells encapsulated in the gel increased dramatically
after 8 days with incubation time and tumorsphere formation.
Since the percentage of live cells in the gel increased with
incubation time (see Figure 2), the decrease in the percentage of
CSCs at day 11 (Figure 3d) was presumably due to the
differentiation of CSCs.
Effect of CD44 Binding Peptide on Tumorsphere
Formation in Hydrogels
It has been shown that CD44BP inhibits breast tumorsphere
formation and maintenance of CSCs in vitro [18]. The focus of this
work was to test the effect of cell binding peptides including
CD44BP that interacts with the CD44 receptor up-regulated on
CSCs, conjugated to the PEGDA hydrogel on tumorsphere
formation in 4T1 tumor cells. Groups included the PEGDA gel
without peptide conjugation (control, labeled as Ctrl in Figure 4),
the gel with CD44BP or scrambled CD44BP (s-CD44BP)
dissolved in the gel and in the culture medium to maintain
constant peptide concentration (labeled as Dis), and the gel with
CD44BP or s-CD44BP conjugated to the gel (covalent attach-
ment, labeled as Conj). Fluorescent images a–d in Figure 3 show
the tumorspheres formed in conj CD44BP, conj s-CD44BP, dis
CD44BP, and dis s-CD44BP, respectively. Tumorsphere forma-
tion was abolished when 4T1 cells were encapsulated in the
CD44BP conjugated gel, indicating the importance of CD44
signaling in the maintenance of CSCs. The effect of CD44BP was
consistent with previous reports [18]. However, CD44BP dissolved
in the gel (images c and d) did not inhibit sphere formation. These
results suggested that CD44BP did not function as a soluble
chemokine to inhibit CSC proliferation but functioned within the
insoluble part of the ECM. We also tested the effect of a scrambled
CD44BP (s-CD44BP). Conjugated or dissolved s-CD44BP had no
significant effect on tumorsphere formation, indicating that
bioactivity was specific to CD44BP.
Figures 4 e and f show the effect of CD44BP on cell number
density and sphere size of 4T1 cells encapsulated in the gel after 9
days of incubation. The 4T1 cell density in the gel reached
146106/mL after 9 days with 1.46105/mL initial cell seeding in
the gel. The density of 4T1 cells in the gel with CD44BP
(conjugated or dissolved and with or without mutation) were lower
compared with the gel without any peptide. However, cells in the
conj CD44BP gel had the strongest effect on cell density and
completely abolished sphere formation (Figure 4a). The expression
of CSC markers, CD44, CD24, ABCG2 and SCA1 was also
determined and the results are shown in Figures 4 g to j,
respectively. 4T1 cells in the CD44BP gel that formed spheres
(conj s-CD44BP, dis CD44BP and dis s-CD44BP) had high
expressions of CD44, ABCG2 and SCA1 and low expression of
CD24. On the other hand, cells in the conj CD44BP gel, which
did not form tumorspheres, had decreased expressions of CD44,
ABCG2 and SCA1, and increased expression of CD24. These
results indicated that tumorsphere formation by 4T1 cells in the
gel correlated with the CSC population.
Effect of CD44 Binding Peptide on Tumor Formation
in vivo
It is well established that tumor growth in vivo requires
a permissive environment that can support vascularization and
matrix remodeling [36,37]. Therefore, a degradable version of
PEGDA gel (dPEGDA) was used to investigate the effect of
CD44BP conjugated to the gel on tumor formation in vivo by the
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encapsulated 4T1 cells. Groups included 4T1 tumorspheres
injected directly without the gel, gels without cell, gels without
peptide conjugation but with 4T1 tumorspheres, and gels with
4T1 cells conjugated with CD44BP. The gels without cell did not
from a visible tumor after 4 weeks (Figure 5). Tumors became
measurable after 10 days with direct subcutaneous injection of
4T1 tumorspheres. 4T1 tumorspheres in the gel without CD44BP
conjugation also formed a tumor after 13 days of inoculation. Even
though the formation of tumor was delayed when cells were
encapsulated in the gel, the growth rate (the slop of the tumor size
Figure 1. Sphere formation and the effect of cell type encapsulated in PEGDA gel on the expression of CSC markers. Representative
fluorescent images of the tumorsphere size and distribution for 4T1 (a), MCF7 (b), and MCF10a (c) cells encapsulated in PEGDA gels (1.46105 cells/ml),
and cultured in stem cell culture medium. Encapsulated cells were stained with phalloidin for cytoskeleton (red) and DAPI for nucleus (blue). Effect of
cell type on cell number density (d) and tumorsphere diameter (e) for tumor cells encapsulated in PEGDA hydrogel and incubated in stem cell culture
medium for 6 or 9 days. The sphere size distribution (f) was determined 9 days after encapsulation. Effect of cell type on CD44 (g), CD24 (h) and
ABCG2 (i) mRNA marker expression for tumor cells encapsulated in PEGDA hydrogel and incubated in stem cell culture medium for 6 or 9 days. RNA
levels of the cells were normalized to those at time zero. A star indicates a statistically significant difference (p,0.05) between the test group and the
groups with different cell type in the same time point (the same diameter range in f). Values are expressed as mean 6 SD (n = 3).
doi:10.1371/journal.pone.0059147.g001
Figure 2. Viability of the cells encapsulated in PEGDA gel. Representative images of live (green) and dead (red) 4T1 cells encapsulated in
PEGDA gels with 5 kPa modulus and cultured in stem cell culture medium for 2 (a), 6 (b) and 12 (c) days. Cells were stained with cAM/EthD for live
(green) and dead (red) cell imaging. The insets in (a) to (c) are live/dead images of 4T1 cells in PEGDA gels with 70 kPa modulus after 2, 6, and 12
(day), respectively.
doi:10.1371/journal.pone.0059147.g002
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curve) did not differ significantly between the group with 4T1 in
PBS and 4T1 in the gel (Figure 5). The observed lag time in tumor
formation for the encapsulated cancer cells is presumably related
to the degradation time of the gel and connection of the tumor
cells to the surrounding tissue [17]. However, 4T1 cells
encapsulated in the conj CD44BP gel did not form a visible
tumor after 4 weeks of inoculation, indicating that CD44BP
conjugated to the gel inhibited tumor formation in vivo.
Comparing the Effect of CD44 Binding Peptide on
Tumorsphere Formation with Integrin and Heparin
Binding Peptides
The effect of CD44BP on tumorsphere formation in the gel
prompted us to test other cell-binding peptides. IBP, an integrin
receptor binding peptide and FHBP, a heparin-binding domain of
fibronectin that binds to cell surface heparin sulfate proteoglycans,
were conjugated to the gel. Groups included 4T1 cell seeded gel
without peptide conjugation, the cell-seeded gel with CD44BP
conjugation, the cell-seeded gel with IBP conjugation, and the cell-
seeded gel with FHBP conjugation. For determination of marker
expression, gels conjugated with a scrambled sequence of the
peptides were also tested. Fluorescent images a–d in Figure 6 show
sphere formation by 4T1 cells in the gels without peptide, with
conj CD44BP, conj IBP, and conj FHBP, respectively. The IBP
conjugation, similar to CD44BP, abolished 4T1 tumorsphere
formation in the gel (Figure 6c). However, tumorsphere formation
increased when 4T1 cells were encapsulated in the FHBP
conjugated gel (Figure 6d). Further characterization of the cells
in these gels (see Figures 6 e–g) showed that the cells in IBP and
CD44BP conjugated gels had reduced cell number, did not form
sphere, and remained as single cells or small cell aggregates
(,25 mm). On the other hand, the cells in FHBP conjugated gel
had higher cell number and larger spheres compared with those in
the gels without peptide conjugation.
To determine whether the size and number density of
tumorspheres in the gel correlated with the CSC sub-population,
CD44 and CD24 expression of the cells in the peptide-conjugated
gels were measured. 4T1 cells in the gels without any peptide
conjugation and with FHBP conjugation had elevated expression
of CD44 marker while the cells in gels conjugated with CD44BP
or IBP had decreased CD44 expression (see Figure 6h). More
Figure 3. CSC population in the cells encapsulated in PEGDA gel. MCF7 cells were encapsulated in PEGDA gels with 5 kPa modulus and
cultured in stem cell culture medium. Cells before encapsulation (a), 3 days (b), 8 days (c) and 11 days (d) after encapsulation were stained with
CD442FITC and CD24-PE antibodies. The population of CD24+, CD44+ and CD44+/CD242 cells was determined by flow cytometry. Flow cytometry
was repeated multiple times on each sample to ascertain reproducibility of the results.
doi:10.1371/journal.pone.0059147.g003
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importantly, the CD44 expression in the cells encapsulated in
FHBP conjugated gel was significantly higher than that without
peptide conjugation. The expression of CD24 in those gels had an
opposite pattern to that of CD44 (see Figure 6i). In breast cancer,
the expression of epidermal growth factor receptor (EGFR) is also
closely related to the maintenance of CSCs [38,39]. The
expression of EGFR marker by 4T1 cells encapsulated in the
peptide-conjugated gels is shown in Figure 6j. Similar to CD44
marker, the expression of EGFR was increased in the cells
encapsulated in FHBP conjugated gel but decreased in CD44BP
and IBP conjugated gels. Furthermore, conjugation of a mutant
sequence of the peptides to the gel had insignificant or limited
effect on tumorsphere formation and the expression of CSC
markers, compared to the wild type (see Figures 6 h–j).
The effect of cell binding peptides on CSC sub-population was
further examined in 4T1 cells by flow cytometry. The percentage
of CD44+/CD242 cells in 4T1 cells cultured without gel
encapsulation was about 6% (Figure 7a). This percentage doubled
to 12% for cells encapsulated in the PEGDA gel without peptide
conjugation (Figure 7b). When 4T1 cells were encapsulated in the
gel conjugated with FHBP, the sub-population of CD44+/CD242
cells was further increased to about 21% (Figure 7c). Conversely,
the fraction of CSC sub-population in the gel decreased to the
original level (5.4% for IBP and 6.5% for CD44BP) when 4T1
cells were encapsulated in the gels conjugated with IBP (Figure 7d)
or CD44BP (Figure 7e) that inhibited sphere formation. These
results suggested that tumorsphere formation by 4T1 cells in the
gel was related to the CSC sub-population.
Effects of Cell Binding Peptides on the Expression of
Other CSC Related Markers
One of the pathways to transform differentiated cancer cells into
CSCs is epithelial to mesenchymal transition (EMT) [40,41]. The
hallmark of EMT is the decreased expression of E-Cadherin and
increased expression of N-Cadherin [42,43]. The expressions of E-
Cadherin and N-Cadherin 3 and 9 days after cells were
encapsulated in the peptide-conjugated gels are shown in
Figures 8 a and b, respectively. At the early time point (3 days),
the expression of E-Cadherin was decreased while the expression
of N-Cadherin was increased in the gel with FHBP, suggesting that
EMT was a possible mechanism for the enhanced tumorsphere
formation in the gel. However, at the later time point (9 days), the
expression of E-Cadherin in the cells grown in FHBP gel was
much higher than that in other groups. This was probably due to
sphere formation in the FHBP gel. E-Cadherin is a cell adhesion
protein and its expression increases with increased cell-cell
interaction [44]. Consistent with that, cells in the IBP and
CD44BP gels, which did not form spheres, had low expressions of
E-Cadherin (see Figure 8b).
The importance of integrins in cancer and CSC maintenance is
well known [45]. Since RGD is an integrin binding peptide, we
examined the expression of integrin aV and b3, two integrin
subunits required for RGD binding, and the expressions are
shown in Figures 7c and 7d, respectively. The expression of
integrin aV and b3 was reduced in cells grown in FHBP and
CD44BP gels, even though the cells in FHBP gel formed spheres
while those in CD44BP gel did not. Interestingly, the expression of
integrin aV and b3 was significantly increased in the cells in IBP
gel. It is possible that blocking integrin signaling by RGD activates
a feedback loop to induce integrin expression. These results
suggest that the expression of integrin does not correlate directly
with tumorsphere formation or CSC maintenance of 4T1 cells.
Conjugation of a mutant sequence of the peptides to the gel had
limited effect on the expression of CSC markers, indicating that
the effect was specific to the wild type.
The expression of vimentin [46] and VEGF, two other markers
related to invasive breast cancer and CSC maintenance [47], was
also determined at the protein level, as shown in Figure 8 e, f. The
expression of vimentin and VEGF was high in cells that formed
spheres, and their expression correlated with the sphere size and
number (see Figures 6 e–f).
Discussion
The concept of CSC niche is based on the evidence that both
normal stem cells and CSCs utilize similar signaling pathways
within a unique microenvironment to maintain stemness. Signal-
ing pathways that have been identified within the stem cell niche
include Notch, Hedgehog, PI3K, Wnt, STAT and TGF-b [48].
Processes such as inflammation, EMT, hypoxia and angiogenesis
Figure 4. Effect of CD44BP on tumorsphere formation and CSC marker expression. Representative fluorescent images of the tumorsphere
size and distribution for 4T1 cells encapsulated in PEGDA gels (1.46105 cells/ml) conjugated with CD44BP (a, conj CD44BP), conjugated with
a scrambled sequence of CD44BP (b, conj s-CD44BP), CD44BP dissolved in the gel (c, dis CD44BP), and s-CD44BP dissolved in the gel (d, dis s-CD44BP)
and cultured in the stem cell culture medium for 9 days. Effect of CD44BP on cell number density (e) and tumorsphere number density (f) for 4T1
tumor cells encapsulated in PEGDA hydrogel and incubated in the stem cell culture medium for 9 days. Effect of CD44BP conjugation on CD44 (g),
CD24 (h), ABCG2 (i) and SCA1 (j) mRNA marker expression for 4T1 tumor cells encapsulated in PEGDA gel and incubated in the stem cell culture
medium for 9 days. RNA levels of the cells were normalized to those at time zero. A star indicates a statistically significant difference (p,0.05)
between the test group and ‘‘Ctrl’’. Two stars indicates a significant difference (p,0.05) between the two CD44BP and s-CD44BP groups within the
same form of peptide addition (Dis or Conj). Values are expressed as mean 6 SD (n = 3).
doi:10.1371/journal.pone.0059147.g004
Figure 5. Effect of CD44BP conjugated to the gel on tumor
formation in vivo. The gel without cell (negative control, light blue),
4T1 tumospheres in suspension (positive control, red), 4T1 cells
encapsulated in the gel without CD44BP (green), and 4T1 cells
encapsulated in the gel with CD44BP (light blue) were inoculated
subcutaneously in syngeneic Balb/C mice. Tumor sizes were measured
daily from post-inoculation day 11 (n = 6/group). Tumor growth was not
observed in the negative control group (the gel without cell) and the
group with 4T1 cells in the gel with CD44BP (the lines for these two
groups are overlapped in the figure).
doi:10.1371/journal.pone.0059147.g005
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within the microenvironment regulate those pathways to sustain
the rare population of CSCs [40].
The cell microenvironment is composed of many cellular and
non-cellular components such as cell binding proteins, growth
factors, and nutrients. In addition, cells also respond to mechanical
properties of the microenvironment such as stiffness and porosity
of the ECM [49]. Therefore, cell fate is determined by the specific
combination of signals presented in its microenvironment. Due to
the complex biochemical composition of the niche, it is difficult to
study the role of individual factors in cell behavior with in vitro
models. We have developed an inert hydrogel as a 3D matrix that
supports the proliferation and maintenance of breast CSCs in
a certain range of elastic moduli without the interference of
proteins, peptides, and other biomolecules in the ECM. In this
study, we investigated the effect of conjugating cell-binding
peptides to the inert gel with controlled stiffness on the
maintenance of stemness of breast CSCs without the interference
of other factors.
CD44 is the most widely used marker to identify breast CSCs.
CD44 is a cell surface proteoglycan that functions in cell-cell and
cell-matrix adhesion. It binds to many ECM ligands including
hyaluronic acid (HA), osteopontin, fibronectin and collagen [50–
53]. It also binds to matrix metalloproteinases (MMPs) and growth
factors to promote tumor invasion and growth [54,55]. Therefore,
CD44 utilizes many signaling pathways to regulate cell behavior,
and its activity depends on conformational changes and post-
translational modifications after ligand binding. CD44BP is
a peptide derived from the D-domain of laminin a5 chain [18].
It binds to CD44 and inhibits lung colonization of tumor cells
in vivo but does not inhibit tumor cell proliferation when added to
the culture medium [18]. In this study, we found that CD44BP
inhibits tumorsphere formation only when conjugated (covalently
attached) to the gel. Dissolving the peptide in the gel or in the
Figure 6. Comparison of tumorsphere formation in PEGDA gels conjugated with CD44BP, IBP, or FHBP. Representative fluorescent
images of the tumorsphere size and distribution for 4T1 cells encapsulated in PEGDA gels (1.46105 cells/ml) without peptide conjugation (a),
conjugation with CD44BP (CD44BP, b), conjugation with RGD integrin-binding peptide (IBP, c) and conjugation with fibronectin-derived binding
peptide (FHBP, d) and cultured in the stem cell culture medium for 9 days. Effect of cell binding peptide on cell number density (e), tumorsphere
number density (f) and sphere size distribution (g) for 4T1 tumor cells encapsulated in PEGDA gel and incubated in the stem cell culture medium for 9
days. Effect of cell binding peptide on CD44 (h), CD24 (i) and EGFR (j) mRNA marker expression for 4T1 tumor cells encapsulated in PEGDA hydrogel
and incubated in the stem cell culture medium for 9 days. RNA levels of the cells were normalized to those at time zero. A star indicates a statistically
significant difference (p,0.05) between the test group and ‘‘Ctrl’’. Two stars indicates a significant difference (p,0.05) between the wild type and
scrambled peptides for the same conjugated peptide. Values are expressed as mean 6 SD (n = 3).
doi:10.1371/journal.pone.0059147.g006
Figure 7. CSC population in cells encapsulated in PEGDA gel conjugated with CD44BP, IBP, or FHBP. 4T1 cells were encapsulated in
PEGDA gels with 5 kPa modulus and cultured in stem cell culture medium. Cells before encapsulation (a), 9 days after encapsulation in the gel
without peptide (b), 9 days in the gel conjugated with FHBP (c), 9 days in the gel conjugated with IBP (d), and 9 days in the gel conjugated with
CD44BP were stained with CD44-FITC and CD24-PE antibodies. The population of CD24+, CD44+ and CD44+/CD242 cells was determined by flow
cytometry. Flow cytometry was repeated multiple times on each sample to ascertain reproducibility of the results.
doi:10.1371/journal.pone.0059147.g007
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medium did not have an effect on tumorsphere formation. This
result suggests that CD44BP does not act as a soluble chemokine
to block or activate CD44 signaling. We speculate that CD44BP
induces a conformational change in CD44 receptor through
a mechanism like receptor clustering. In previous studies, another
CD44 binding peptide, A6, was found to enhance cell adhesion to
HA and induce FAK and MEK phosphorylation in a CD44
dependent manner in breast and ovarian cancer cells [56]. A6 also
inhibited cancer cell migration and metastasis in vivo [56]. It is
Figure 8. Expression of the markers related to CSC maintenance in cells grown in the gel conjugated with CD44BP, IBP, or FHBP.
Effect of cell binding peptide on N-Cadherin (a), E-Cadherin, (b), integrin aV (c), and integrin b3 (D) mRNA marker expression for 4T1 tumor cells
encapsulated in PEGDA hydrogel and incubated in the stem cell culture medium for 9 days. Effect of cell binding peptide on vimentin (e) and VEGF (f)
protein expression. The protein expression was determined by western blot and quantified with imageJ. Actin was used as the internal control and
the protein expressions were normalized to those at time zero. RNA levels of the cells were normalized to those at time zero. A star indicates
a statistically significant difference (p,0.05) between the test group and ‘‘Ctrl’’. Values are expressed as mean 6 SD (n = 3).
doi:10.1371/journal.pone.0059147.g008
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unclear whether CD44BP binding also causes phosphorylation of
these kinases in a CD44 dependent manner.
ECM signaling mainly occurs through the integrin family of
proteins [57]. The main integrin receptor is aVb3 and it has been
implicated in the pathogenesis of several types of cancer. Down-
regulation of aVb3 integrin sensitized cancer cells to radiotherapy
[58]. Inhibition of aVb3 integrin blocked the CSC driven tumor
formation in a prostate xenograft model [59]. Further studies
suggest that blocking aVb3 integrin leads to redistribution of b-
catenin from the nucleus to the cytoplasm [19]. Nuclear
localization of b-catenin is known to be one of the mechanisms
for maintaining stemness. Therefore, aVb3 integrin-mediated
signaling is required for the maintenance of CSCs. RGD peptide,
a well-known ligand of aVb3 integrin receptor, blocks the integrin
mediated cell adhesion. In this study, RGD peptide (IBP) without
conjugation to the hydrogel did not affect tumorsphere formation.
Since the PEGDA hydrogel did not have cell-binding motifs,
blocking cell adhesion sites by RGD might not have a significant
effect. However, the matrix rigidity is sensed by the actin
cytoskeleton through integrin receptors [60–62]. A recent study
showed that membrane-bound RGD can induce the clustering of
integrin receptors when cells are seeded on RGD peptide
conjugated lipid membranes [63]. Furthermore, integrin receptor
clustering stimulates local actin polymerization and leads to
cytoskeleton remodeling [63]. We speculate that RGD peptide
conjugated to the PEGDA hydrogel causes clustering of the
integrin receptors, which in turn, alters cells’ ability to sense matrix
rigidity. Since tumorsphere formation in PEGDA hydrogel is
rigidity dependent, it would be interesting to determine whether
breast cancer cells can form spheres in the RGD conjugated
PEGDA hydrogel under a different elastic modulus.
The RGD integrin binding peptide is present in many ECM
components, but there are other binding motifs in the ECM. For
example, fibronectin has a RGD-independent heparin-binding
domain in the C-terminus that binds to heparin sulfate
proteoglycans on the surface of tumor cells [20,64]. In this study,
we found that unlike CD44 and RGD binding peptides, FHBP
conjugated to the gel enhanced tumorsphere formation. It has
been shown that FHBP promotes focal adhesion formation in
culture cells [20] and it likely activates the focal adhesion kinase
(FAK). Several lines of evidence have indicated the role of FAK in
promoting breast cancer invasion and metastasis [65,66] and FAK
is required for the survival of breast cancer cells in the absence of
cell attachment. The expression of FAK dominant negative
mutant in breast cancer cells leads to deactivation and degradation
of endogenous FAK and cell apoptosis without matrix attachment
[67]. Therefore, FHBP, unlike CD44BP and IBP that block the
receptor signaling, may activate FAK and promote CSC survival.
As a result, 4T1 cells encapsulated in the gel conjugated with
FHBP formed larger and greater number of spheres.
Fibronectin is a mesenchymal marker and its expression is
increased during the process of EMT. In the EMT process, certain
epithelial cells loose cell-cell adhesion and invade the local tissue. It
is thought that a similar transformation occurs during cancer
metastasis [68]. Recent studies have shown that EMT induction is
sufficient to turn differentiated cancer cells into CSCs [40,41]. A
recent study showed that mammary tumor cells displayed a more
differentiated phenotype when cultured on collagen coated
substrates, while they displayed an invasive phenotype and
EMT-related gene expression pattern when cultured on fibronec-
tin coated substrates [69]. Therefore, FHBP may induce EMT
which in turn enhance tumorsphere formation. In the EMT
process, the expression of E-Cadherin is down regulated but E-
Cadherin may also be up-regulated with increasing cell-cell
interaction. Consistent with this, the expression of E-Cadherin
was initially reduced in our study in the cells encapsulated in
FHBP gel but increased at a later time point. The expression
pattern of some of the examined EMT markers also suggests that
enhanced EMT may contribute to the increased tumorsphere
formation in FHBP conjugated gels.
This study also included the mutant forms of the peptides.
Although the mutants did not affect tumorsphere formation, they
slightly affected the expression of some of the markers. It is possible
that the mutants bind to the corresponding receptors but with
much lower affinity or non-specifically. In summary, this study
demonstrated that cell adhesion peptides could either increase or
diminish CSC population in the inert 3D PEGDA hydrogel cell
culture system, as the mechanisms for CSC maintenance among
these peptides are different.
Conclusion
Using the 3D PEGDA matrix with a certain stiffness, we
demonstrated that the cell adhesion CD44 binding peptide
(CD44BP), RGD integrin binding peptide (IBP), and fibronectin-
derived heparin binding peptide (FHBP) can be individually
conjugated to the inert PEGDA gel and their effect on the
maintenance of breast cancer stem cells can be investigated
without the interference of other factors. The CD44BP and IBP
conjugated to the inert gel completely abolished tumorsphere
formation by the encapsulated 4T1 breast cancer cells while FHBP
enhanced tumorsphere formation compared to those without
peptide. The inert 3D hydrogel cell culture system provides a novel
tool to investigate the individual effect of factors in the
microenvironment on maintenance of CSCs without the in-
terference of other factors.
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